NCT03438032Completed
Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD
Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD Using High Throughput Single-cell RNA-Seq
Source: ClinicalTrials.gov · Last updated 14 Nov 2024
Brief summary (registry, in English)
Alveolar macrophages isolated from bronchoalveolar lavage (BAL) fluid from systemic sclerosis (SSc) patients with clinically significant lung fibrosis will be studied at baseline and at 6 months after enrollment to assess longitudinally the presence and persistence of an emergent, pro-fibrotic alveolar macrophage population, using single cell RNA-Seq technology to measure the individual transcriptome from each cell.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 10 (actual)
- First submitted
- 12 Feb 2018
- Start date
- 28 Jun 2018
- Primary completion date
- 12 Oct 2022
- Lead sponsor
- Northwestern University
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT03438032
What you commit to
- Study type: Observational
- Participants enrolled: 10
- From 28 Jun 2018 to the primary completion date, 12 Oct 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- diagnosis of an overlap syndrome, such as lupus or rheumatoid arthritis
- comorbidities of uncontrolled congestive heart failure, cancer not in remission, HIV, or chronic liver disease
- known or suspected infection in the past 3 months
Other
- unable to provide informed consent in English
- currently pregnant or nursing
- current smoker or former smoker (greater than 10 pack years)
- leukopenia
- anemia
- BMI greater than or equal to 30 kg/m2
Who the study is looking for
- meet 2013 ACR criteria for diagnosis of SSc
- have radiographic evidence for ILD and a forced vital capacity \<70% on PFT
- have not taken immune suppression in the last 2 months OR have taken a stable dose of mycophenolate mofetil, rituximab, or prednisone less than or equal to 10 mg for at least 6 months
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Northwestern University Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.